Literature DB >> 32044315

Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis.

Robert F Schwabe1, Ira Tabas2, Utpal B Pajvani3.   

Abstract

Nonalcoholic fatty liver disease is the most prevalent liver disease worldwide, affecting 20%-25% of the adult population. In 25% of patients, nonalcoholic fatty liver disease progresses to nonalcoholic steatohepatitis (NASH), which increases the risk for the development of cirrhosis, liver failure, and hepatocellular carcinoma. In patients with NASH, liver fibrosis is the main determinant of mortality. Here, we review how interactions between different liver cells culminate in fibrosis development in NASH, focusing on triggers and consequences of hepatocyte-macrophage-hepatic stellate cell (HSC) crosstalk. We discuss pathways through which stressed and dead hepatocytes instigate the profibrogenic crosstalk with HSC and macrophages, including the reactivation of developmental pathways such as TAZ, Notch, and hedgehog; how clearance of dead cells in NASH via efferocytosis may affect inflammation and fibrogenesis; and insights into HSC and macrophage heterogeneity revealed by single-cell RNA sequencing. Finally, we summarize options to therapeutically interrupt this profibrogenic hepatocyte-macrophage-HSC network in NASH.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Drug Development; Metabolic Syndrome; Noninvasive Biomarkers; Pediatric Obesity

Mesh:

Year:  2020        PMID: 32044315      PMCID: PMC7682538          DOI: 10.1053/j.gastro.2019.11.311

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  164 in total

1.  [Erythrocyte ATPase activity as a function of the age of the subjects and the cell].

Authors:  F Canestrari; L Cucchiarini; R Giacchi; M Di Quirico; B Biagiarelli
Journal:  Boll Soc Ital Biol Sper       Date:  1988-09

2.  Blockade of YAP alleviates hepatic fibrosis through accelerating apoptosis and reversion of activated hepatic stellate cells.

Authors:  Hai-Xia Yu; Yao Yao; Fang-Tian Bu; Yu Chen; Yu-Ting Wu; Yang Yang; Xin Chen; Yan Zhu; Qin Wang; Xue-Yin Pan; Xiao-Ming Meng; Cheng Huang; Jun Li
Journal:  Mol Immunol       Date:  2019-01-11       Impact factor: 4.407

3.  Hippo pathway activity influences liver cell fate.

Authors:  Dean Yimlamai; Constantina Christodoulou; Giorgio G Galli; Kilangsungla Yanger; Brian Pepe-Mooney; Basanta Gurung; Kriti Shrestha; Patrick Cahan; Ben Z Stanger; Fernando D Camargo
Journal:  Cell       Date:  2014-06-05       Impact factor: 41.582

4.  Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Veeral Ajmera; Charlie C Park; Cyrielle Caussy; Seema Singh; Carolyn Hernandez; Ricki Bettencourt; Jonathan Hooker; Ethan Sy; Cynthia Behling; Ronghui Xu; Michael S Middleton; Mark A Valasek; Claire Faulkner; Emily Rizo; Lisa Richards; Claude B Sirlin; Rohit Loomba
Journal:  Gastroenterology       Date:  2018-04-13       Impact factor: 22.682

Review 5.  TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy.

Authors:  Yemsratch T Akalu; Carla V Rothlin; Sourav Ghosh
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

6.  Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner.

Authors:  Utpal B Pajvani; Carrie J Shawber; Varman T Samuel; Andreas L Birkenfeld; Gerald I Shulman; Jan Kitajewski; Domenico Accili
Journal:  Nat Med       Date:  2011-07-31       Impact factor: 53.440

7.  Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair.

Authors:  Chang-Goo Huh; Valentina M Factor; Aránzazu Sánchez; Koichi Uchida; Elizabeth A Conner; Snorri S Thorgeirsson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-30       Impact factor: 11.205

Review 8.  Apoptosis and necroptosis in the liver: a matter of life and death.

Authors:  Robert F Schwabe; Tom Luedde
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-12       Impact factor: 46.802

9.  Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease.

Authors:  Puneet Puri; Faridoddin Mirshahi; Onpan Cheung; Ramesh Natarajan; James W Maher; John M Kellum; Arun J Sanyal
Journal:  Gastroenterology       Date:  2007-10-26       Impact factor: 22.682

10.  Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis.

Authors:  Michael Estep; Rohini Mehta; Gary Bratthauer; Lakshmi Alaparthi; Fanny Monge; Simon Ali; Dinan Abdelatif; Zahra Younoszai; Maria Stepanova; Zachary D Goodman; Zobair M Younossi
Journal:  BMC Gastroenterol       Date:  2019-02-11       Impact factor: 3.067

View more
  92 in total

1.  Targeted Delivery of Notch Inhibitor Attenuates Obesity-Induced Glucose Intolerance and Liver Fibrosis.

Authors:  Lauren R Richter; Qianfen Wan; Di Wen; Yuqi Zhang; Junjie Yu; Jin Ku Kang; Changyu Zhu; Elizabeth L McKinnon; Zhen Gu; Li Qiang; Utpal B Pajvani
Journal:  ACS Nano       Date:  2020-05-22       Impact factor: 15.881

Review 2.  Fibrosis: from mechanisms to medicines.

Authors:  Neil C Henderson; Florian Rieder; Thomas A Wynn
Journal:  Nature       Date:  2020-11-25       Impact factor: 49.962

3.  Regulation of peroxisome proliferator-activated receptor-gamma activity affects the hepatic stellate cell activation and the progression of NASH via TGF-β1/Smad signaling pathway.

Authors:  Xi-Xi Ni; Xiao-Yun Li; Qi Wang; Jing Hua
Journal:  J Physiol Biochem       Date:  2020-11-14       Impact factor: 4.158

4.  Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease.

Authors:  Suguru Ikeda; Takaaki Sugihara; Yoshiki Hoshino; Yukako Matsuki; Takakazu Nagahara; Jun-Ichi Okano; Sonoko Kitao; Youhei Fujioka; Kazuhiro Yamamoto; Hajime Isomoto
Journal:  Yonago Acta Med       Date:  2020-08-07       Impact factor: 1.641

Review 5.  Maladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis.

Authors:  Changyu Zhu; Ira Tabas; Robert F Schwabe; Utpal B Pajvani
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-13       Impact factor: 46.802

6.  Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure?

Authors:  Andre J Jeyarajan; Raymond T Chung
Journal:  J Infect Dis       Date:  2020-11-27       Impact factor: 5.226

Review 7.  The Power of Plasticity-Metabolic Regulation of Hepatic Stellate Cells.

Authors:  Parth Trivedi; Shuang Wang; Scott L Friedman
Journal:  Cell Metab       Date:  2020-11-23       Impact factor: 27.287

8.  c-Rel orchestrates energy-dependent epithelial and macrophage reprogramming in fibrosis.

Authors:  Jack Leslie; Marina García Macia; Saimir Luli; Julie C Worrell; William J Reilly; Hannah L Paish; Amber Knox; Ben S Barksby; Lucy M Gee; Marco Y W Zaki; Amy L Collins; Rachel A Burgoyne; Rainie Cameron; Charlotte Bragg; Xin Xu; Git W Chung; Colin D A Brown; Andrew D Blanchard; Carmel B Nanthakumar; Morten Karsdal; Stuart M Robinson; Derek M Manas; Gourab Sen; Jeremy French; Steven A White; Sandra Murphy; Matthias Trost; Johannes L Zakrzewski; Ulf Klein; Robert F Schwabe; Ingmar Mederacke; Colin Nixon; Tom Bird; Laure-Anne Teuwen; Luc Schoonjans; Peter Carmeliet; Jelena Mann; Andrew J Fisher; Neil S Sheerin; Lee A Borthwick; Derek A Mann; Fiona Oakley
Journal:  Nat Metab       Date:  2020-11-09

9.  Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis.

Authors:  Junjie Yu; Changyu Zhu; Xiaobo Wang; KyeongJin Kim; Alberto Bartolome; Paola Dongiovanni; Katherine P Yates; Luca Valenti; Michele Carrer; Thorsten Sadowski; Li Qiang; Ira Tabas; Joel E Lavine; Utpal B Pajvani
Journal:  Sci Transl Med       Date:  2021-06-23       Impact factor: 17.956

Review 10.  Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus.

Authors:  Daniel Ferguson; Brian N Finck
Journal:  Nat Rev Endocrinol       Date:  2021-06-15       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.